Join Now

Category Archives: BioUtah News

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK – ENROLLMENT TO STOP DUE TO SUCCESS

By admin | Published December 7, 2023

SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal […]

| Comments Off on SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK – ENROLLMENT TO STOP DUE TO SUCCESS

BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems

By Natalie Themm | Published December 7, 2023

BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems

| Tagged | Comments Off on BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems

Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA

By Natalie Themm | Published November 30, 2023

Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA

| Tagged | Comments Off on Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

By Natalie Themm | Published November 30, 2023

SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success

| Tagged | Comments Off on BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Seek Labs Announces Completion of Office Expansion to Support Business Growth

By Natalie Themm | Published November 30, 2023

Seek Labs Announces Completion of Office Expansion to Support Business Growth

| Tagged | Comments Off on Seek Labs Announces Completion of Office Expansion to Support Business Growth

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

By Natalie Themm | Published November 30, 2023

Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.

| Tagged | Comments Off on Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

By Natalie Themm | Published November 30, 2023

LED BY CLARKE CAPITAL, THE NEW FUNDING ROUND WILL ACCELERATE THE COMPANY’S DRUG DISCOVERY PIPELINE

| Tagged | Comments Off on Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

By Natalie Themm | Published November 30, 2023

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

| Tagged | Comments Off on Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

By Natalie Themm | Published November 30, 2023

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

| Tagged | Comments Off on Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

By Natalie Themm | Published November 16, 2023

Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests

| Tagged | Comments Off on Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease

By Natalie Themm | Published November 16, 2023

PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization

| Tagged | Comments Off on Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease

2023 Utah Life Sciences Summit Recap and Gallery

By admin | Published November 9, 2023

BioUtah yesterday held its 2023 Utah Life Sciences Summit, presented by Mayer Brown. Every year, the Summit is the largest gathering of Utah’s life sciences industry. This year was no exception. Following welcome remarks from Gov. Spencer Cox, a distinguished line-up of top executives addressed a packed house. Keynote speaker, Joseph Smith, chief scientific officer […]

| Comments Off on 2023 Utah Life Sciences Summit Recap and Gallery

A Special Thanks To Our Legacy and Platinum Elite Members